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Pailure to Protect the Myocardium
gainst Ischemia/Reperfusion Injury
fter Chronic Atorvastatin Treatment Is
ecaptured by Acute Atorvastatin Treatment
Potential Role for Phosphatase and
ensin Homolog Deleted on Chromosome Ten?
wabena Mensah, MBCHB, Mihaela M. Mocanu, PHD, Derek M. Yellon, DSC, FACC
ondon, United Kingdom
OBJECTIVES We sought to ascertain whether chronic oral therapy with atorvastatin protects against
ischemia/reperfusion (I/R) injury.
BACKGROUND We have recently shown that acute atorvastatin treatment protects against reperfusion-
induced injury by activating the PI3K/Akt/eNOS pathway. However, many patients are on
chronic statin therapy, and it is necessary to investigate whether this, in itself, provides a
therapeutic advantage.
METHODS Sprague-Dawley rats were orally treated for one day, three days, one week, or two weeks with
20 mg/kg of atorvastatin or vehicle, after which the hearts underwent 35 min of ischemia and
120 min reperfusion (IR). Two additional groups were treated for one or two weeks with
atorvastatin and then received a supplementary dose of 40 mg/kg before IR. The risk zone was
determined using Evans blue and infarct size (IR%) using triphenyltetrazolium chloride
staining.
RESULTS Treatment with atorvastatin for one and three days significantly reduced infarct size versus
controls (38.9 3.1% vs. 56.4 2.3%; 39.3 2.4% vs. 61.3 3.8%, respectively). However,
after one or two weeks of treatment, no protection was observed (52.6  3.8% vs. 58.6 
4.3%; 58.3  2.7% vs. 52.4  5.7%, respectively). Surprisingly, a supplementary dose of
atorvastatin recaptured the protection in the groups treated chronically (36.2  2.8% vs. 58.6
 4.3%; 26.8  1.5% vs. 51.2  6.7%, at one and two weeks, respectively). Interestingly, we
observed an increased level of phosphatase and tensin homolog deleted on chromosome ten
(PTEN), the phosphatidylinositol-3 kinase inhibitor, in the chronic treated hearts.
CONCLUSIONS In conclusion, atorvastatin appears to have an acute protective effect that wanes with time
associated with an increase in PTEN levels. This waning protection can be recaptured by an
acute high dose given immediately before IR. These results may have protential clinical
relevance. (J Am Coll Cardiol 2005;45:1287–91) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.021Cardiology Foundation
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mhe 3-hydroxy-3-methylglutaryl CoA reductase inhibitor
rugs, commonly termed statins, are widely used for the
reatment of hypercholesterolaemia, a significant risk factor
or ischemic heart disease. They act by inhibiting the
ate-limiting step in cholesterol synthesis, the conversion of
See page 1292
eta-hydroxy-beta-methylglutaryl-CoA to mevalonate (1).
everal studies have shown an improved rate of morbidity
nd mortality from treatment with statins (2–5). This
enefit has been mainly attributed to their cholesterol-
owering properties. However, further analyses of these
tudies appear to show an extra benefit above and beyond
From The Hatter Institute and Centre for Cardiology, University College London
ospital and Medical School, London, United Kingdom. Pfizer pharmaceuticals
upported this work with a research grant and supplied the atorvastatin. However, this
tudy was undertaken completely independent of the company. This work has been
ritten solely by the authors, and Pfizer have not seen its contents.b
Manuscript received October 5, 2004; revised manuscript received November 1,
004, accepted January 4, 2005.he cholesterol-lowering effects. These other effects have
een termed the pleiotropic effects of statins. One such
ffect is its ability to activate the PI3K)/Akt pro-survival
athway (6), a pathway that, if activated before or after
schemia, has been shown to confer an intrinsic protection
rom ischemia/reperfusion (I/R) injury (7,8). Statins also
ave been shown in animal studies to reduce infarct size
hen given before ischemia (9) or just before reperfusion
10), this effect having been shown to be mediated via PI3K.
However, although it is apparent that such treatment
ith statins appears to be beneficial when given acutely
10–12), recent studies have shown a detrimental effect after
rolonged oral administration, with a reduction in adeno-
ine triphosphate and creatinine phosphate levels in dog
yocardium (13,14). It is important to appreciate that
lthough acute activation of the PI3K/Akt pathway is
eneficial, promoting cell survival and having an antiapo-
totic effect (15–17), chronic activation would cause cardio-
egaly (18–20) and could lead to tumor formation, as has
een shown in other tissues (21–23). It would therefore
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Chronic Atorvastatin Treatment and PTEN April 19, 2005:1287–91ollow that there should be intrinsic cellular mechanisms
ble to control PI3K/Akt activation over the course of time.
n this regard, phosphatase and tensin homolog deleted on
hromosome ten (PTEN) is the phosphatase that reverses
he effect of PI3K (24). Therefore, our study examined both
cute and chronic oral treatment with atorvastatin on I/R
njury. In addition, we measured the level of the phospha-
ase PTEN, a known inhibitor of the PI3K pro-survival
athway.
ETHODS
torvastatin treatment. Male Sprague-Dawley rats were
sed in all experiments. Animal care was performed in
ccordance with The Guidance on the Operation of the
nimals (Scientific Procedure) Act of 1986. Rats weighing
etween 200 and 250 g (n 6 per group) were orally treated
gavaged) for either one day, three days, one week, or two
eeks with 20 mg/kg of atorvastatin in 1% methylcellulose
r methylcellulose alone (control group), after which the
earts were isolated and subjected to I/R on a Langendorff
pparatus (as described in the next section). An additional
wo groups consisted of male Sprague-Dawley rats treated
or one week or two weeks with 20 mg/kg atorvastatin, after
hich they received a further 40 mg/kg of atorvastatin 3 to
h before being subjected to myocardial I/R injury on the
angendorff apparatus.
angendorff perfusion. The rats were anesthetized with
00 mg/kg of pentobarbitone and heparinized with 300 IU
ntraperitoneally. The hearts were rapidly excised and placed
n ice-cold buffer, then mounted on a Langendorff apparatus
nd retrogradely perfused under constant pressure of 75 mm
g with modified Krebs-Henseleit buffer, pH 7.35 to 7.45.
yocardial temperature was monitored constantly by a
emperature probe inserted in the pulmonary artery outflow
rack and maintained at 37 0.5°C. Pressure and heart rate
ere measured using an isovolumetric, fluid-filled latex
alloon inserted into the left ventricle via the excised left
trial appendage. Coronary flow also was measured and
ecorded at regular intervals. A 3-0 surgical suture was
laced around the left main coronary artery, a short distance
rom its origin, and the two ends of the suture were pulled
hrough a small piece of plastic tubing to form a snare.
xperimental protocol for ischemia/reperfusion. The
solated hearts were allowed to stabilize for 30 to 40 min,
fter which time each heart was subjected to 35 min of
Abbreviations and Acronyms
eNOS  endothelial nitric oxide synthase
I/R  ischemia/reperfusion
PI3K  phosphatidylinositol-3 kinase
PTEN  phosphatase and tensin homolog deleted on
chromosome tenegional ischemia, which was induced by tightening the wnare around the coronary artery, followed by 120 min of
eperfusion, which was induced by releasing the snare.
nfarct size determination. After the reperfusion period,
he suture around the coronary artery was re-ligated, and
.25% Evans blue dye was injected into the heart to
elineate the non-risk area. The hearts were then frozen and
liced into 2-mm thick sections and incubated in triphenyl-
etrazolium chloride for 10 to 15 min at 37°C. The hearts
ere subsequently fixed in formalin for 24 h and then the
isk and infarct areas traced onto acetate sheets. The
ercentage of infarcted tissue (triphenyltetrazolium chloride
egative) developed in the area at risk (Evans blue negative)
as calculated using computerized planimetry (Summa
ketch III, Summagraphics, Seymour, Connecticut) and
xpressed as a percentage of ischemia/reperfusion.
estern blot analyses. SAMPLE COLLECTION. In separate
xperiments, hearts from Sprague-Dawley rats, gavaged
ither for one day, three days, one week, or two weeks with
0 mg/kg of atorvastatin in 1% methylcellose or methylcel-
ulose alone, were retrogradely perfused, allowed to stabilize
or 20 to 30 min, and then were subjected to 35 min of
egional ischemia followed by 5 min of reperfusion (n  3
er group). At the end of this period, the area at risk was
elineated using Evans blue as previously described, excised,
reeze clamped, and stored at 80°C for further analysis.
TEN ANALYSIS. Proteins were extracted by homogeniza-
ion and centrifugation in cold suspension buffer containing
in mmol/l): NaCl 100, TRIS 10 (pH 7.6), ethylenediamine
etraacetic acid 1 (pH 8.0), sodium pyrophosphate 2, so-
ium fluoride 2, beta-glycerophosphate 2, phenyl methyl
ulfonyl fluoride 0.1 g/ml, and 1 g/ml each of aprotinin,
eupeptin, trypsin inhibitor, and protease inhibitor. Protein
ontent was determined using a bicinchoninic acid assay
Pierce, Rockford, Illinois). Furthermore, the samples were
enaturated by boiling in suspension buffer, which con-
ained (in mmol/l): Tris 100 (pH 6.8), dithiothreitol 200,
odium dodecyl sulfate 2%, bromophenol blue 0.2%, and
lycerol 20%. Proteins were separated using sodium dodecyl
ulfate polyacrylamide gel electrophoresis and then trans-
erred on Hybond ECL nitrocellulose membrane (Amersham
iosciences, Amersham, United Kingdom) overnight. Levels
f PTEN were detected using primary and secondary anti-
odies from Cell Signalling Ltd. (United Kingdom) and the
nhanced chemiluminescence ECL Western blotting re-
gent (Amersham Biosciences). The bands were compared
sing computerized planimetry (NIH Image 1.63).
tatistical analysis. All data were expressed as mean 
tandard error of the mean. The data were analyzed using
he analysis of variance factorial test. A p value of0.05 was
onsidered significant.
ESULTS
nfarct/risk ratio. Oral treatment with atorvastatin for one
r three days significantly reduced infarct size compared
ith controls (38.9  3.1% vs. 56.4  2.3% and 39.3 
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ata shown in Figure 2 demonstrates that, after one or two
eeks of oral treatment, the protection was lost (52.6 
.8% vs 58.6  4.3%; 58.32.7% vs. 52.4  5.7%,
reatment vs. control group). Importantly, however, an
dditional high dose of atorvastatin (given within 3 to 4 h
efore the I/R injury) recaptured the protection, reducing
nfarct size from 58.6 4.3% to 36.2 2.8% after one week
nd from 51.2  6.7% to 26.8  1.5% after two weeks of
ral treatment (Fig. 2).
estern blot for PTEN. After the various treatment
egimes with atorvastatin, the level of PTEN in the heart
as measured. Gavage with methylcellulose was used as the
ontrol. No significant difference was found in PTEN levels
Fig. 3) after acute atorvastatin treatment. After one day and
hree days of oral administration, the relative densitometry
alues were 840  230 versus 905  147 and 928  16
ersus 837  124 in methylcellulose- and atorvastatin-
reated groups, respectively.
Interestingly, when comparing one week of treatment
ith methylcellulose versus one week of treatment with
torvastatin (Fig. 4), we observed a significant increase in
TEN level (606  149 vs. 1,309  193, respectively, p 
.05). The same difference could be observed when com-
aring the two-week methylcellulose treatment versus two-
eek atorvastatin treatment (3,475  643 vs. 6,383  45,
espectively, p  0.05; Fig. 5).
igure 2. Infarction developed in the risk zone in hearts treated for one or
wo weeks with atorvastatin or methylcellulose.   a supplementary dose
igure 1. Infarction developed in the risk zone in hearts treated for one
r three days with atorvastatin or methylcellulose. *p  0.05. I/R 
schemia/reperfusion.f atorvastatin given a few hours before ischemia/reperfusion (I/R). *p 
.05.
s
oISCUSSION
he results presented in this study show that atorvastatin
rotects the myocardium after short-term (acute) treatment
ut that this protection is lost after chronic administration.
e have also shown that, using the Western blotting
echnique, chronic treatment with atorvastatin leads to an
ncrease in the levels of PTEN, the phosphatase that
nactivates PI3K. Interestingly, a further dose of atorvasta-
in, given just before ischemia/reperfusion, restores this
rotection.
The beneficial effects of statins in the treatment of
schemic heart disease are now well documented, with
eneficial effects shown in a number of clinical studies, as
reviously mentioned (2–5,25). Initially, these effects were
hought to be entirely due to cholesterol lowering because
here seemed to be a strong correlation between cholesterol
evels and adverse effects. However, a number of trials (4,26)
ave shown beneficial effects in the presence of mildly
levated or even normal cholesterol levels. These results led
o the investigation of the other beneficial effects of statins,
he so-called, pleiotropic effects. A wide variety of studies
ave been performed to investigate these effects (27–29),
igure 3. Level of phosphatase and tensin homolog deleted on chromo-
ome ten (PTEN) in hearts treated with methylcellulose or atorvastatin for
ne or three days. (A) Western blots; (B) relative densitometry.
igure 4. Level of phosphatase and tensin homolog deleted on chromo-
ome ten (PTEN) in hearts treated with methylcellulose or atorvastatin for
ne week. (A) Representative blots; (B) relative densitometry. *p  0.05.
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Chronic Atorvastatin Treatment and PTEN April 19, 2005:1287–91hich include inhibition of smooth muscle proliferation
nd platelet aggregation, anti-inflammatory effects, and
nhancement of endothelial function.
Although most studies have examined endothelial func-
ion (for review see, McFarlane et al. [30]), a number of
tudies have investigated the direct effects of short-term
reatment with statins on infarct size and myocardial func-
ion in the setting of I/R in the myocardium (9,31).
owever, in the in vivo techniques the effects upon inflam-
ation, platelet aggregation, and immunomodulation
ould be expected to play an important part in the protec-
ion observed with statins. Surprisingly, statins have been
emonstrated to directly activate the PI3K/Akt pro-survival
athway (10,32,33). We have previously demonstrated the
mportance of PI3kinase and its downstream effector, Akt,
s well as endothelial nitric oxide synthase in the protection
bserved with acute atorvastatin treatment (10). Although
e do not observe any protection with chronic atorvastatin
reatment, we cannot be sure at this stage whether this is
ue to a down-regulation of the activity of these kinases,
lthough our studies relating to PTEN may suggest such an
ffect (as discussed later in this article).
The PI3K/Akt pathway has been shown to be of great
mportance in the intrinsic protection of the myocardium
efore ischemia (7,34) and at reperfusion (8), and the
ctivation of this pathway provides an explanation for the
rotection observed with acute treatment with atorvastatin
35).
From our study, it appears that chronic treatment with
torvastatin does not demonstrate any protection; however,
dditional acute atorvastatin treatment (on top of chronic)
ppears to restore this protection. The mechanism under-
ying this restored protection is at this stage unclear. It is
ossible that in this setting, other survival pathways that are
nown to protect the myocardium from I/R injury (35) are
lso activated. These pathways include the extracellular
igure 5. Level of phosphatase and tensin homolog deleted on chromo-
ome ten (PTEN) in hearts treated with methylcellulose or atorvastatin for
wo weeks. (A) Representative blots; (B) relative densitometry. *p  0.05.ignal-regulated kinase 1/2, which is also known to exhibit srosstalk with PI3K (36). Alternatively, it could simply be as
consequence of a dose-dependent phenomenon.
Our data relating to the loss of protection, as a result of
hronic treatment, are in accordance with other studies
14,37,38), indicating a detrimental effect of long-term
tatin treatment on myocardial function. Paradoxically, the
xplanation for this loss of protection with chronic treat-
ent with atorvastatin may also be as a consequence of the
bility of statins to activate the PI3K/Akt pathway. As
entioned, the activation of PI3K is beneficial for the cells
n short term because, among other effects, it promotes
ntiapoptotic mechanisms (15–17) through the generation
f the second messenger PI-3,4,5-trisphosphate. However, a
rolonged activation of PI3K will be associated with cardio-
egaly (18–20) or tumor formation (21,22), as has been
emonstrated to be the case in many cancers. Therefore,
ormal cells possess intrinsic mechanisms for limiting chronic
ctivation of PI3K. In this respect, the main suppressor is
TEN, which hydrolyzes PI-3,4,5-trisphosphate in its pre-
ursor and PI3K substrate, PI-4,5-diphosphate (39). Inter-
stingly, our Western blot data showed an increase in the
evels of PTEN after chronic treatment with atorvastatin in
he hearts treated for one and two weeks. Importantly, this
ncrease was associated with a loss of protection after I/R
njury. It already has been demonstrated in other cellular
ystems that PTEN activity is regulated by its protein level
40). Therefore, we would hypothesize that this increase of
TEN may be responsible for the loss of protection ob-
erved in the chronic atorvastatin-treated hearts. This im-
ortant adaptive mechanism, which could account for this
oss of protection, may be necessary to regulate growth-
nducing kinases.
The pro-survival kinases have been examined in great
etail in the setting of preconditioning (7,8,34) and
eperfusion-injury salvage (35); however, there is a paucity
f literature with regards to the role of phosphatases in this
etting. A few studies have investigated the effect of phos-
hatase inhibitors on myocardial protection (41,42); how-
ver, no studies have examined the PI3 kinase-specific
hosphatase, PTEN, in the setting of I/R injury. Further
etailed studies investigating the importance of PTEN in
/R injury need to be undertaken.
onclusions. In this work, we present evidence that acute
reatment with atorvastatin can protect the myocardium from
ubsequent I/R injury; however, with chronic or long-term
reatment, this protection is lost. Interestingly the protection
ppears to be recaptured by an increased dose of atorvastatin
iven 3 to 4 h before the ischemia/reperfusion. We also
uggest a potential mechanism that could explain the loss of
he protective effect of chronic administration of atorvasta-
in; this being via an increase in the level of the tumor
uppressor, PTEN, which is a ubiquitous regulator of the
I3K activity. Therefore, investigating such a mechanism
ay provide a new and novel approach in the strategy of
tatin administration. Moreover, such studies could be
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